These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38894848)

  • 21. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
    Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
    JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry.
    Lucijanić M; Bušić N; Bistrović P; Papić I; Zelenika Margeta M; Babić P; Barčan M; Pasarić A; Mustapić M; Piskač Živković N; Ortner Hadžiabdić M; Lucijanić T; Lukšić I; Baršić B
    Croat Med J; 2022 Dec; 63(6):536-543. PubMed ID: 36597565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.
    Olender SA; Perez KK; Go AS; Balani B; Price-Haywood EG; Shah NS; Wang S; Walunas TL; Swaminathan S; Slim J; Chin B; De Wit S; Ali SM; Soriano Viladomiu A; Robinson P; Gottlieb RL; Tsang TYO; Lee IH; Hu H; Haubrich RH; Chokkalingam AP; Lin L; Zhong L; Bekele BN; Mera-Giler R; Phulpin C; Edgar H; Gallant J; Diaz-Cuervo H; Smith LE; Osinusi AO; Brainard DM; Bernardino JI;
    Clin Infect Dis; 2021 Dec; 73(11):e4166-e4174. PubMed ID: 32706859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world evidence of survival benefit of remdesivir: study of 419 propensity score-matched patients hospitalized over the alpha and delta waves of COVID-19 in New Orleans, LA.
    Salvadori N; Fridman M; Chiang M; Chen L; Wang C; Lee E; Fonseca V; Fusco DN; Jourdain G; Drouin AC
    Front Med (Lausanne); 2024; 11():1390164. PubMed ID: 38818394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19.
    Arber N; Shah PL; Assoumou L; Rokx C; De Castro N; Bakhai A; Soriano Viladomiu A; Mateu L; Lumbreras C; Estrada V; Curran A; Sellier PO; Duffy A; Fletcher C; Mozaffari E; Haubrich R; Hodgkins P; Pozniak A; Raffi F
    Infect Dis Now; 2023 Oct; 53(7):104760. PubMed ID: 37454762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remdesivir and Mortality in Patients With Coronavirus Disease 2019.
    Diaz GA; Christensen AB; Pusch T; Goulet D; Chang SC; Grunkemeier GL; McKelvey PA; Robicsek A; French T; Parsons GT; Doherty G; Laurenson C; Roper R; Hadlock J; Cover CJ; Footer B; Robinson P; Micikas M; Marfori JE; Cronenweth C; Mukkamala Y; Mackiewicz J; Rai E; Matson MD; Davila J; Rueda J; Tipton R; Algren H; Ward BC; Malkoski S; Gluckman T; Tallman GB; Arguinchona H; Hammond TC; Standaert S; Christensen J; Echaiz JF; Choi R; McClung D; Pacifico A; Fee M; Sarafian F; Berrington WR; Goldman JD
    Clin Infect Dis; 2022 May; 74(10):1812-1820. PubMed ID: 34409431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study.
    Garibaldi BT; Wang K; Robinson ML; Betz J; Caleb Alexander G; Andersen KM; Joseph CS; Mehta HB; Korwek K; Sands KE; Fisher AM; Bollinger RC; Xu Y
    Clin Infect Dis; 2022 Aug; 75(1):e516-e524. PubMed ID: 34910128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remdesivir: A Review in COVID-19.
    Blair HA
    Drugs; 2023 Sep; 83(13):1215-1237. PubMed ID: 37589788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States.
    Chokkalingam AP; Hayden J; Goldman JD; Li H; Asubonteng J; Mozaffari E; Bush C; Wang JR; Kong A; Osinusi AO; Gottlieb RL
    JAMA Netw Open; 2022 Dec; 5(12):e2244505. PubMed ID: 36454570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study.
    Mengato D; Mazzitelli M; Francavilla A; Bettio M; Sasset L; Presa N; Pivato L; Lo Menzo S; Trevenzoli M; Venturini F; Gregori D; Cattelan AM
    Clin Exp Med; 2023 Oct; 23(6):2749-2756. PubMed ID: 36961678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study.
    Pierce-Williams RAM; Burd J; Felder L; Khoury R; Bernstein PS; Avila K; Penfield CA; Roman AS; DeBolt CA; Stone JL; Bianco A; Kern-Goldberger AR; Hirshberg A; Srinivas SK; Jayakumaran JS; Brandt JS; Anastasio H; Birsner M; O'Brien DS; Sedev HM; Dolin CD; Schnettler WT; Suhag A; Ahluwalia S; Navathe RS; Khalifeh A; Anderson K; Berghella V
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100134. PubMed ID: 32391519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexamethasone for Inpatients With COVID-19 in a National Cohort.
    Mourad A; Thibault D; Holland TL; Yang S; Young AR; Arnold Egloff SA; Thomas LE
    JAMA Netw Open; 2023 Apr; 6(4):e238516. PubMed ID: 37067800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial.
    Rosas IO; Diaz G; Gottlieb RL; Lobo SM; Robinson P; Hunter BD; Cavalcante AW; Overcash JS; Hanania NA; Skarbnik A; Garcia-Diaz J; Gordeev I; Carratalà J; Gordon O; Graham E; Lewin-Koh N; Tsai L; Tuckwell K; Cao H; Brainard D; Olsson JK
    Intensive Care Med; 2021 Nov; 47(11):1258-1270. PubMed ID: 34609549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remdesivir for the Treatment of COVID-19: A Narrative Review.
    Godwin PO; Polsonetti B; Caron MF; Oppelt TF
    Infect Dis Ther; 2024 Jan; 13(1):1-19. PubMed ID: 38193988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis.
    Beckerman R; Gori A; Jeyakumar S; Malin JJ; Paredes R; Póvoa P; Smith NJ; Teixeira-Pinto A
    Sci Rep; 2022 Jun; 12(1):9622. PubMed ID: 35688854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
    Kalil AC; Mehta AK; Patterson TF; Erdmann N; Gomez CA; Jain MK; Wolfe CR; Ruiz-Palacios GM; Kline S; Regalado Pineda J; Luetkemeyer AF; Harkins MS; Jackson PEH; Iovine NM; Tapson VF; Oh MD; Whitaker JA; Mularski RA; Paules CI; Ince D; Takasaki J; Sweeney DA; Sandkovsky U; Wyles DL; Hohmann E; Grimes KA; Grossberg R; Laguio-Vila M; Lambert AA; Lopez de Castilla D; Kim E; Larson L; Wan CR; Traenkner JJ; Ponce PO; Patterson JE; Goepfert PA; Sofarelli TA; Mocherla S; Ko ER; Ponce de Leon A; Doernberg SB; Atmar RL; Maves RC; Dangond F; Ferreira J; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd L; Tomashek KM; Beigel JH;
    Lancet Respir Med; 2021 Dec; 9(12):1365-1376. PubMed ID: 34672949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remdesivir for the treatment of COVID-19.
    Grundeis F; Ansems K; Dahms K; Thieme V; Metzendorf MI; Skoetz N; Benstoem C; Mikolajewska A; Griesel M; Fichtner F; Stegemann M
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014962. PubMed ID: 36695483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world effectiveness of sotrovimab and remdesivir for early treatment of high-risk hospitalized COVID-19 patients: A propensity score adjusted retrospective cohort study.
    Koh LP; Chua SL; Vasoo S; Toh MPHS; Cutter JN; Nah PH; Leo YS; Tay JX; Young BE; Lye DC; Ong SWX
    J Med Virol; 2023 Feb; 95(2):e28460. PubMed ID: 36602046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study.
    Rajme-López S; Martinez-Guerra BA; Román-Montes CM; Tamez-Torres KM; Tello-Mercado AC; Tepo-Ponce KM; Segura-Ortíz Z; López-Aguirre A; Gutiérrez-Mazariegos ODR; Lazcano-Delgadillo O; Nares-López R; González-Lara MF; Kershenobich-Stalnikowitz D; Sifuentes-Osornio J; Ponce-de-León A; Ruíz-Palacios GM
    Ther Adv Infect Dis; 2024; 11():20499361241236582. PubMed ID: 38545451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.